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Appendix 1: Search Strategy 
Scientific and related database searches 
PubMed, Embase, CINAHL, Web of Science, the Cochrane Database of Systematic 
Reviews (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), Health 
Technology Assessment Database (HTA), NIHR Health Technology Assessment, NICE 
Technology appraisals, 
Medline (PubMed) 
Prescription length*[title/abstract] OR prescription duration*[title/abstract] OR medication 
duration*[title/abstract] OR “medication length”[title/abstract] OR “length of 
prescription”[title/abstract] OR “length of prescriptions”[title/abstract] OR “duration of 
prescription”[title/abstract] OR “duration of prescriptions”[title/abstract] OR “durations of 
prescriptions”[title/abstract] OR “drug prescribing”[title/abstract] OR “multiple drug 
prescriptions”[title/abstract] OR prescribing pattern*[title/abstract] OR prescription 
pattern*[title/abstract] OR prescribing behavior*[title/abstract] OR prescribing 
behaviour*[title/abstract] OR prescribing practice*[title/abstract] OR prescribing 
standard*[title/abstract] OR (installment[title/abstract] AND dispensing[title/abstract]) OR 
repeat prescri*[title/abstract] OR “repeat dispensing”[title/abstract] OR prescribing 
interval*[title/abstract] OR prescription interval*[title/abstract] OR “28 day 
supply”[Title/abstract] OR “34 day supply”[title/abstract] OR ("28 day"[title/abstract] AND 
("drug supply"[title/abstract] OR prescribing[title/abstract] OR prescription[title/abstract])) OR 
“56 day supply”[title/abstract] OR ("56 day"[title/abstract] AND ("drug supply"[title/abstract] 
OR prescribing[title/abstract] OR prescription[title/abstract])) OR “28 day drug 
limit”[title/abstract] OR “56 day drug limit”[title/abstract] OR “one month 
prescription”[title/abstract] OR “one month prescriptions”[title/abstract] OR “1 month 
prescription”[title/abstract] OR “1 month supply”[title/abstract] OR “one month 
supply”[title/abstract] OR “3 month prescriptions”[title/abstract]OR “three month 
prescription”[title/abstract] OR “three month prescriptions”[title/abstract] OR “3 month 
prescription”[title/abstract] OR “3 month supply”[title/abstract] OR “three month 
supply”[title/abstract] OR “90 day supply”[title/abstract] OR “30 day supply”[title/abstract] OR 
“60 day supply”[title/abstract] OR dosage unit*[title/abstract] OR “prescription 
standardization”[title/abstract] OR  “prescription standardisation”[title/abstract] OR 
prescription restriction*[title/abstract] OR prescribing restriction*[title/abstract] OR “restricting 
prescriptions”[title/abstract] OR “restricting medication”[title/abstract] OR medication 
restriction*[title/abstract] OR dispensing restriction*[title/abstract] OR prescribing 
trend*[title/abstract] OR prescription trend*[title/abstract] OR dispensing trend*[title/abstract] 
OR “trends in dispensing”[title/abstract] OR "trends in prescribing"[title/abstract] OR 
prescription suppl*[title/abstract] OR medication suppl*[title/abstract] OR term 
prescription*[title/abstract] OR ((short course*[title/abstract] OR long course*[title/abstract]) 
AND (prescription*[title/abstract] OR medication*[title/abstract])) OR “short 
prescription”[title/abstract] OR “long prescription”[title/abstract] OR “short 
prescriptions”[title/abstract] OR “long prescriptions”[title/abstract] OR standardized 
prescri*[title/abstract] OR “standardised prescription”[title/abstract] OR “standardised 
prescribing”[title/abstract] OR (Standardization[title/abstract] AND (prescribing[title/abstract] 
OR prescription*[title/abstract])) OR (Standardisation[title/abstract] AND 
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(prescribing[title/abstract] OR prescription*[title/abstract])) OR individualized 
prescri*[title/abstract] OR individualised prescri*[title/abstract] OR 
(individualization[title/abstract] AND prescrib*[title/abstract]) OR 
(individualisation[title/abstract] AND prescrib*[title/abstract]) OR Drug Prescriptions/trends 
OR Drug Prescriptions/supply and distribution  
Results: 8,242 – animal = 8,207 
Embase 
(prescription* NEAR/2 length*):ti,ab OR (prescription* NEAR/2 duration*):ti,ab OR 
(medication* NEAR/2 duration*):ti,ab OR (medication* NEAR/2 length*):ti,ab OR “drug 
prescribing”:ti,ab OR “multiple drug prescriptions”:ti,ab OR (prescri* NEXT/1 pattern*):ti,ab 
OR (prescribing NEXT/1 behaviour*):ab,ti (prescribing NEXT/1 behavior*):ab,ti OR 
(prescribing NEXT/1 practice*):ab,ti OR (prescribing NEXT/1 standard*):ab,ti OR “installment 
dispensing”:ti,ab OR (repeat NEXT/1 prescri*):ti,ab OR (repeat NEXT/1 dispens*):ti,ab OR 
(prescri* NEXT/1 interval*):ti,ab OR (prescri* NEXT/1 interval*):ti,ab OR ((28 OR 30 OR 34 
OR 56 OR 60 OR 90) NEXT/1 day NEXT/1 supply):ti,ab OR ((28 OR 30 OR 34 OR 56 OR 
60 OR 90) NEXT/1 day NEXT/1 drug NEXT/1 supply):ti,ab OR ((28 OR 30 OR 34 OR 56 OR 
60 OR 90) NEXT/1 day NEXT/1 prescri*):ti,ab OR ((28 OR 30 OR 56 OR 60 OR 90) NEXT/1 
day NEXT/1 drug NEXT/1 limit):ti,ab OR “one month prescription”:ti,ab OR “1 month 
prescription”:ti,ab OR “one month supply”:ti,ab OR “1 month supply”:ti,ab OR (3 NEXT/1 
month NEXT/1 prescription*):ti,ab OR (three NEXT/1 month NEXT/1 prescription*):ti,ab OR 
“3 month supply”:ti,ab OR “three month supply”:ti,ab OR (dosage NEXT/1 unit*) OR 
“prescription standardization”:ti,ab OR “prescription standarisation”:ti,ab OR (prescri* 
NEAR/1 restrict*):ti,ab OR (medication* NEAR/1 restrict*):ti,ab OR (dispensing NEXT/1 
restrict*):ti,ab OR (prescri* NEAR/2 trends):ti,ab OR (dispensing NEAR/2 trends):ti,ab OR 
((prescription OR medication) NEXT/1 suppl*):ti,ab OR ((short OR long) NEXT/1 (course OR 
term) NEXT/1 (prescription* OR medication*)):ti,ab OR ((short OR long) NEXT/1 
prescription*):ti,ab OR ((standardised OR standardized OR standardization OR 
standardisation) NEXT/2 prescri*):ti,ab OR  ((individualized OR individualized OR 
individualization OR individualisation) NEXT/1 prescri*):ti,ab  
Results:  6,266 – duplicates/animal = 3,600 
CINAHL 
TI “prescription length*” OR AB “prescription length*” OR TI "prescription duration*" OR AB 
"prescription duration*" OR TI "length* of prescription*" OR AB "length* of prescription*" OR 
TI "duration* of prescription*" OR AB "duration* of prescription*" OR TI "drug prescribing" 
OR AB "drug prescribing" OR  TI "multiple drug prescriptions" OR AB "multiple drug 
prescriptions"  OR TI "prescri* pattern*" OR AB "prescri* pattern*" OR  TI "prescribing 
behavior*" OR AB "prescribing behavior*" OR TI "prescribing behaviour*" OR AB 
"prescribing behaviour*" OR TI "prescribing practice*" OR AB "prescribing practice*"  OR TI 
"prescribing standard*" OR AB "prescribing standard*" OR TI "installment dispensing" OR 
AB "installment dispensing" OR TI "repeat prescri*" OR AB "repeat prescri*" OR TI "28 day 
supply" OR AB "28 day supply" OR  TI "30 day supply" OR AB "30 day supply" OR TI "30 
day drug supply" OR AB "30 day drug supply" OR TI "28 day drug supply" OR AB "28 day 
drug supply" OR TI "34 day drug supply" OR AB "34 day drug supply" OR  TI "34 day 
supply" OR AB "34 day supply OR TI "28 day prescri*" OR AB "28 day prescri*"  OR  TI "30 
day prescri*" OR AB "30 day prescri*"  OR TI "34 day prescri*" OR AB "34 day prescri*"  OR 
TI "28 day drug limit*" OR AB "28 day drug limit*" OR TI "30 day drug limit*" OR AB "30 day 
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drug limit*" OR TI "34 day drug limit*" OR AB "34 day drug limit*" OR TI "56 day supply" OR 
AB "56 day supply" OR TI "56 day drug supply" OR AB "56 day drug supply" OR TI "56 day 
prescri*" OR AB "56 day prescri*" OR TI "56 day drug limit*" OR AB "56 day drug limit*"  OR 
TI "60 day supply" OR AB "60 day supply" OR TI "60 day drug supply" OR AB "60 day drug 
supply" OR TI "60 day prescri*" OR AB "60 day prescri*" OR TI "60 day drug limit*" OR AB 
"60 day drug limit*" OR  TI "90 day supply" OR AB "90 day supply" OR TI "90 day drug 
supply" OR AB "90 day drug supply" OR TI "90 day prescri*" OR AB "90 day prescri*" OR TI 
"90 day drug limit*" OR AB "90 day drug limit*"  TI "one month prescription*" OR AB "one 
month prescription*" OR TI "1 month prescription*" OR AB "1 month prescription*" OR TI "1 
month supply" OR AB "1 month supply"  OR TI “one month supply” OR AB “one month 
supply” OR TI "three month prescription*" OR AB "three month prescription*" OR TI "3 
month prescription*" OR AB "3 month prescription*" OR TI "3 month supply" OR AB "3 
month supply" OR TI "three month supply" OR AB "three month supply" OR TI "dosage 
unit*" AND AB "dosage unit*"  OR  TI "prescription standardization*" OR AB "prescription 
standardization*" OR TI "prescription standardisation*" OR AB "prescription 
standardisation*" OR TI "prescri* restriction*" OR AB "prescri* restriction*" OR TI "restricting 
prescription*" OR AB "restricting prescription*" OR TI "restricting medication*" OR AB 
"restricting medication*" OR TI "medication restriction*" OR AB "medication restriction*"  OR 
TI "dispensing restriction*" OR AB "dispensing restriction*" OR TI "prescri* trend*" OR AB 
"prescri* trend*" OR TI "dispensing trend*" OR AB "dispensing trend*" OR TI "trends in 
dispensing" OR AB "trends in dispensing" OR TI "trends in prescribing" OR AB "trends in 
prescribing" OR TI "prescription suppl*" OR AB "prescription suppl*" OR TI "medication 
suppl*" OR AB "medication suppl*" OR TI "term prescription*" OR AB "term prescription*" 
OR TI "short course prescription*" OR AB "short course prescription*" OR TI "long course 
prescription*" OR AB "long course prescription*" OR TI "short course medication*" OR AB 
"short course medication*" OR TI "long course medication*" OR AB "long course 
medication*"  OR TI "short prescription*" OR AB "short prescription*" OR TI "long 
prescription*" OR AB "long prescription*" OR TI "standardized perscri*" OR AB 
"standardized perscri*" OR TI "standardised perscri*" OR AB "standardised perscri*" OR TI 
"standarization of prescri*" OR AB "standarization of prescri*" OR TI "standarisation of 
prescri*" OR AB "standarisation of prescri*" OR TI "individualized prescri*" OR AB 
"individualized prescri*" OR TI "individualised prescri*" OR AB "individualised prescri*" OR TI 
"individualization prescri*" OR AB "individualization prescri*" OR TI "individualisation 
prescri*" OR AB "individualisation prescri*"    
Results: 1,737 - duplicates = 367 
Web of Science 
Refined by: [excluding] DOCUMENT TYPES: ( LETTER OR NEWS ITEM OR EDITORIAL 
MATERIAL OR BOOK CHAPTER OR NOTE OR BOOK REVIEW OR DISCUSSION ) AND 
[excluding] WEB OF SCIENCE CATEGORIES: ( OPERATIONS RESEARCH 
MANAGEMENT SCIENCE OR VETERINARY SCIENCES OR COMPUTER SCIENCE 
ARTIFICIAL INTELLIGENCE OR MATHEMATICAL COMPUTATIONAL BIOLOGY OR 
COMPUTER SCIENCE THEORY METHODS OR METEOROLOGY ATMOSPHERIC 
SCIENCES OR MECHANICS OR FORESTRY OR TELECOMMUNICATIONS OR 
MATHEMATICS OR MATERIALS SCIENCE MULTIDISCIPLINARY OR ECOLOGY OR 
FOOD SCIENCE TECHNOLOGY OR AUTOMATION CONTROL SYSTEMS OR 
ASTRONOMY ASTROPHYSICS ) AND [excluding] WEB OF SCIENCE CATEGORIES: ( 
STATISTICS PROBABILITY OR POLYMER SCIENCE OR MATHEMATICS 
INTERDISCIPLINARY APPLICATIONS OR AGRICULTURE DAIRY ANIMAL SCIENCE OR 
PLANT SCIENCES OR PHYSICS PARTICLES FIELDS OR BIOCHEMISTRY MOLECULAR 
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BIOLOGY OR OCEANOGRAPHY OR ENGINEERING MULTIDISCIPLINARY ) AND 
[excluding] RESEARCH AREAS: ( WATER RESOURCES OR MATERIALS SCIENCE OR 
MINING MINERAL PROCESSING OR METALLURGY METALLURGICAL ENGINEERING 
OR MATHEMATICS ) AND [excluding] WEB OF SCIENCE CATEGORIES: ( PHYSICS 
FLUIDS PLASMAS OR ENERGY FUELS OR AGRICULTURE MULTIDISCIPLINARY ) 
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 
TS=(prescription* NEAR/2 length*) OR TS=(prescription* NEAR/2 duration*) OR 
TS=("duration of medication*")  OR TS=("length* of medication*") OR TS=(“drug 
prescribing”) OR TS=(“multiple drug prescriptions”) OR TS=("prescription pattern*") OR 
TS=("prescribing pattern*") OR TS=(“prescri* pattern*”) OR TS=("prescribing behavior*") OR 
TS=("prescribing behaviour*") OR TS=("prescription behavior*") OR TS=("prescription 
behaviour*")  OR TS=(“prescri* practice*”) OR TS=("prescription standard*") OR 
TS=("prescribing standard*") OR TS=(“installment dispensing”) OR TS=(“repeat dispens*”) 
OR TS=("repeat* prescription*") OR TS=("repeat* prescribing*") OR TS=("prescribing 
interval*") OR TS=("prescription interval*") OR TS=(“28 day supply”) OR TS=(“30 day 
supply”) OR TS=(“34 day supply”) OR TS=(“56 day supply”) OR TS=(“60 day supply”) OR 
TS=(“90 day supply”) OR TS=(“28 day drug supply”) OR TS=(“30 day drug supply”) OR 
TS=(“34 day drug supply”) OR TS=(“56 day drug supply”) OR TS=(“60 day drug supply”) OR 
TS=(“90 day drug supply”) OR TS=(“28 day prescri*”) OR TS=(“30 day prescri*”) OR 
TS=(“34 day prescri*”) OR TS=(“56 day prescri*”) OR TS=(“60 day prescri*”) OR TS=(“90 
day prescri*”) OR TS=(“28 day drug limit*”) OR TS=(“30 day drug limit*”) OR TS=(“34 day 
drug limit*”) OR TS=(“56 day drug limit*”) OR TS=(“60 day drug limit*”) OR TS=(“90 day drug 
limit*”) OR TS=(“one month prescription”) OR TS=(“1 month prescription”) OR TS=(“one 
month supply”) OR TS=(“1 month supply”) OR TS=(“three month prescription*”) OR TS=(“3 
month prescription*”) OR TS=(“three month supply”) OR TS=(“3 month supply”) OR 
TS=(“dosage unit*”) OR TS=(“prescription standardization”) OR TS=(“prescription 
standardisation”) OR TS=(prescri* NEAR/1 restrict*) OR TS=(medication* NEAR/1 restrict*) 
OR TS=(“dispensing restrict*”) OR TS=(dispensing NEAR/2 trends) OR TS=(prescri* 
NEAR/2 trends) OR TS=(“prescription suppl*”) OR TS=(“medication suppl*”) OR TS=(“short 
term prescription*”) OR TS=(“short term medication*”) OR TS=(“short course prescription*”) 
OR TS=(“short course medication*”) OR TS=(“long term prescription*”) OR TS=(“long term 
medication*”) OR TS=(“long course prescription*”) OR TS=(“long course medication*”) OR 
TS=(“short prescription*”) OR TS=(“long prescription*”) OR TS=((standardized OR 
standardised OR standardization OR standardisation) NEAR/2 prescri*) OR 
TS=((individualized OR indvidualised OR individualization OR individualization) NEAR/1 
(prescription* OR prescribing)) 
8,592 – duplicates/animal: 3,002 
Cochrane 
“length of prescription”:ti,ab OR “prescription length”:ti,ab OR “prescription duration”:ti,ab OR 
“drug prescribing”:ti,ab OR “multiple drug prescription*”:ti,ab OR “prescri* pattern”:ti,ab OR 
“prescribing behavior”:ti,ab OR “prescri practice”:ti,ab OR “prescri* standard*”:ti,ab OR 
“repeat dispens*”:ti,ab OR “repeat prescri*”:ti,ab OR “prescri* interval*”:ti,ab OR "28 day 
supply":ti,ab OR "30 day supply":ti,ab or "34 day supply":ti,ab OR "60 day supply":ti,ab or 
"90 day supply":ti,ab OR "28 day prescri*":ti,ab OR "30 day prescri*":ti,ab or "34 day 
prescri*":ti,ab OR "60 day prescri*":ti,ab or "90 day prescri*":ti,ab or “56 day prescri*”:ti,ab 
OR “one month prescription”:ti,ab OR “1 month prescription”:ti,ab OR “one month 
supply”:ti,ab OR “1 month supply”:ti,ab OR “three month prescription”:ti,ab OR “3 month 
prescription”:ti,ab OR “3 month supply”:ti,ab OR “three month supply”:ti,ab OR “dosage 
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unit*”:ti,ab OR “prescription standardization”:ti,ab OR “prescri* restriction*”:ti,ab OR 
“medication restrict*”:ti,ab OR “dispensing restriction*”:ti,ab OR “dispensing NEAR/2 
trend*”:ti,ab OR “prescription NEAR/2 trend*” OR “medication supply”:ti,ab OR “medication 
supplies”:ti,ab OR “short term prescription*”:ti,ab OR “long term prescription*”:ti,ab OR 
“prescription suppl*”:ti,ab OR ((standardized OR standardised OR standardization OR 
standardisation) NEAR/2 prescri*) OR ((individualized OR indvidualised OR individualization 
OR individualization) NEAR/1 (prescription* OR prescribing)) 
After duplicates: 69 
NICE 
“length of prescription” OR “prescription length” OR “medication length” OR “prescription 
trends” OR “medication trends” OR “multiple prescriptions” OR “30 day supply” OR “60 day 
supply” OR “90 day supply” OR “one month supply” OR “three month supply” OR 
“prescription supply” OR “medication supply” OR “short term prescription” OR “long term 
prescription” OR “standardised prescription” OR “individualised prescription” OR “prescribing 
behaviour”  
**added 5 records.  
Total 
15,250 (NO year limits) 
Grey literature searches 
NYAM Grey Literature Report, OAISTER, OpenGrey 
NYAM 
prescribing patterns; prescription length; one month supply;  28 day supply; length of 
prescription; multiple drug prescription; dispensing restriction; prescribing trends; prescribing 
behavior; individualized prescribing; individualized prescription; month supply;  
Oaister 
Ti: Prescribing patterns; ti: length of prescription; ti: prescription standardization; ti: 
dispensing regulation; ti: 30 day supply; ti: repeat dispensing; ti: medication prescription; ti: 
individualized prescri*; ti: multiple drug prescri*; ti: short term prescri*; ti: long term prescri*; 
ti: prescription trends; ti: prescribing trends;  
OpenGrey 
“prescribing patterns”; “prescription length”; “prescription standardization”; “dispensing 
regulations”; “prescription trends”; “prescription patterns”; “individualized prescri*”; 
“prescribing trends”; “28 day supply”; “multiple prescriptions”; 
Total 
14 
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Appendix 2: PRISMA flow chart   
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Appendix 3: Characteristics of included studies 
Reference, 
country, and 
study design 
Aim Participants Setting Medication 
evaluated 
Comparison Total sample 
size  
(patients 
unless 
otherwise 
stated) 
Outcomes 
measured 
Study 
length 
Batal 2007[23] 
USA 
 
Retrospective 
cohort 
 
To determine the effect 
of prescription size on 
patients' adherence to 
hyperlipidaemia 
therapy.  
Patients receiving 
ongoing care and 
medication for 
hyperlipidaemia 
Primary care 
clinic serving a 
predominantly 
minority and 
indigent 
population 
• Lipid lowering agents 
(statins) 
60-day supply of 
medication (based on 
modal supply of more 
than 45 days) compared 
to 30 day supply (based 
on modal supply of less 
than 45 days) 
3,386 • Adherence 
• Health (risk 
only) 
3 years 
Domino 
2011[35] 
USA 
 
Retrospective 
before and after 
controlled study 
with a cost 
consequence 
analysis 
 
To estimate the effect 
of two separate policy 
changes in the North 
Carolina Medicaid 
program: (1) reduced 
prescription lengths 
from 100 to 34 days' 
supply, and (2) 
increased co-payments 
for brand name 
medications. 
Adult Medicaid 
recipients who use 
medications for 
chronic conditions 
Not explicitly 
reported; claims 
data from two 
centres for 
Medicare and 
Medicaid 
Services 
 
• Anti-depressants  
• Anti-hypertensives  
• Anti-psychotics 
• Diabetic medication 
(sulfonylureas) 
• Seizure disorder 
medications 
• Lipid lowering agents 
(statins) 
Reduced prescription 
length from 100 days to 
34 days 
268,050 • Adherence 
• Cost 
18 months 
Faris 2010[24] 
USA 
*Abstract 
 
Retrospective 
cohort 
 
To determine the 
impact of days' supply 
on waste. To compare 
medication waste rates 
between patients with a 
90-day supply and 
those with a 30-day 
supply in 4 speciality 
therapeutic categories. 
Patients with four 
specialty 
therapeutic 
categories: multiple 
sclerosis, 
rheumatoid arthritis, 
oncology and 
growth hormone 
Not explicitly 
reported 
Medications for: 
• Multiple sclerosis 
• Rheumatoid arthritis 
• Oncology 
• Growth hormone 
 
90-day supply 
compared to 30-day 
supply 
Not reported • Wastage 21 months 
(360 day 
study period 
and 270-day 
washout 
period (to 
determine 
drop off) 
Hermes 
2010[25] 
To compare adherence 
within three chronic 
medication classes by 
Members with a first 
claim  
Not explicitly 
reported 
• Anti-hypertensives 
• Diabetic medications 
90-day supply 
compared to 30-day 
at 270 days: 
183,666 
• Adherence 540 days 
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Reference, 
country, and 
study design 
Aim Participants Setting Medication 
evaluated 
Comparison Total sample 
size  
(patients 
unless 
otherwise 
stated) 
Outcomes 
measured 
Study 
length 
*Abstract 
USA 
 
Retrospective 
cohort 
 
days’ supply and 
evaluate potential 
adherence predictors. 
• Lipid lowering agents  supply at 540 days: 
112,220 
Jiang 2007[26] 
*Abstract 
USA  
 
Retrospective 
cohort 
 
To compare adherence 
and wastage among 
30-day retail program, 
mandatory 90-day retail 
program and voluntary 
90-day retail program. 
Patients who were 
new to ACE-
inhibitor statins or 
SSRIs 
Not explicitly 
reported; 
pharmacy 
claims data 
(Walgreens) 
• Anti-depressants 
(SSRIs) 
• Anti-hypertensives 
(ACE inhibitors) 
• Lipid lowering agents 
(statins) 
90-day supply, either 
mandatory or 
voluntarily, compared to 
30-day supply 
1,685  • Adherence 
• Wastage 
1 year 
Murphy 
2012[27] 
USA 
 
Retrospective 
cohort 
 
To examine medication 
wastage for patients 
filling 90-day supplies 
of medication 
compared with those 
filling 30-day 
prescriptions. 
Adults with repeat 
prescriptions for 
ongoing care 
Not explicitly 
reported; 
pharmacy 
claims data 
(Walgreens) 
• Anti-depressants 
(SSRIs; Tricyclics) 
• Diabetic medications 
(biguanides; insulin)  
• Anti-hypertensives 
(Alpha-beta 
blockers; ACE 
inhibitors; 
Angiotensin II 
receptor antagonists; 
calcium channel 
blockers; 
cardioselective beta-
blockers; Loop 
diuretics; Thiazides) 
• Lipid lowering agents 
(statins; fibric acid 
derivatives) 
90-day supply 
compared to 30-day 
supply 
 
90 day supply stratified 
in two prescription 
fulfilment groups: mail 
and retail 
60,358 • Wastage 1 year 
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Reference, 
country, and 
study design 
Aim Participants Setting Medication 
evaluated 
Comparison Total sample 
size  
(patients 
unless 
otherwise 
stated) 
Outcomes 
measured 
Study 
length 
• Thyroid hormones 
Pfeiffer 2012[28] 
USA 
 
Retrospective 
cohort 
 
To examine whether 
receipt of an initial 90-
day supply of an 
antidepressant was 
associated with better 
or worse longer-term 
antidepressant 
coverage compared 
with patients who 
initially received less 
than a 90-day supply. 
Adult patients newly 
diagnosed with 
major depression 
Not explicitly 
reported; 
pharmacy 
claims from 
Veterans Affairs 
National 
Registry for 
Depression. 
Variety of 
settings 
including 
primary care, 
mental health 
clinics and 
inpatient 
services 
• Anti-depressants 90-day supply 
compared to less than 
90-day supply 
383,634 • Adherence 
• Other (clinical 
encounters) 
7 years  
Ryvkin 2009[29] 
*Abstract  
USA  
 
Retrospective 
cohort 
 
To quantify medication 
wastage for Lipid 
Lowering Agents, 
Antihypertensive 
Therapy and Proton 
Pump Inhibitors. 
Patients new to 
therapy 
Not explicitly 
reported; 
pharmacy 
claims data 
(Medco Health 
Solutions) 
• Anti-hypertensives 
• Lipid-lowering 
agents  
• Anti-ulcers (Proton 
pump inhibitors) 
30 to 90-day supply and 
more than 90-day 
supply compared to 30-
day supply 
43,318 • Wastage Not reported 
Schectman 
2002[32] 
USA 
 
Cross-sectional 
study 
To evaluate the 
association between 
multiple demographic 
and prescription factors 
with the adherence 
behaviour of an 
indigent rural 
population to determine 
whether such factors 
could assist in targeting 
Low-income 
patients without 
prescription 
insurance coverage, 
on hypertension, 
hypercholesterolemi
a or oral diabetes 
medication. 
Academic 
internal 
medicine 
practice 
42 medications: 
• Anti-hypertensives 
• Diabetic medication 
• Lipid lowering agents  
n/a looking at factors 
associated with 
adherence among a 
population receiving 
standard care. 
Prescription length 
varied, maximum supply 
was 90 days. 
1,984 • Adherence 9 months 
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Reference, 
country, and 
study design 
Aim Participants Setting Medication 
evaluated 
Comparison Total sample 
size  
(patients 
unless 
otherwise 
stated) 
Outcomes 
measured 
Study 
length 
interventions. 
Schmittdiel 
2015[33] 
USA  
 
Cross-sectional 
study 
To examine the 
relationship between 
Medicare STAR 
medication adherence 
metrics and modifiable 
health system-level 
characteristics in a 
cohort of Medicare-
aged diabetes patients 
Adults aged 65 
years and older with 
diabetes 
Not explicitly 
reported; 
electronic health 
data from the 
three largest 
Kaiser 
Permanente 
health care 
delivery sites 
• Anti-hypertensives 
(ACE inhibitors; 
angiotensin II 
receptor blockers) 
• Diabetic medications 
(oral anti-
hyperglycemics) 
• Lipid lowering agents 
(statins) 
n/a looking at four 
health-system level 
factors associated with 
adherence. Days' 
supply was derived from 
pharmacy electronic 
medication dispensing 
records. Categorised 
as: less than 30-day, 31 
to 60-day, 61 to 90-day 
and more than 90-day 
supply. 
236,025 • Adherence Up to 1 year 
Steiner 1993[30] 
USA  
 
Retrospective 
cohort 
 
To determine whether 
large prescriptions (≥90 
days' supplies) 
enhance the acquisition 
of maintenance 
medications by 
patients. 
Patients who had 
received digoxin 
prescriptions in the 
previous year 
(ongoing care) 
Not explicitly 
reported; 
pharmacy 
records from ten 
Veteran Affairs 
Medical centres 
• Digoxin 31 to 89-day supply and 
more than 90-day 
supply compared to 30-
day supply 
120 • Adherence 14 months 
Taitel 2012[31] 
USA 
 
Retrospective 
cohort with a 
cost 
consequence 
analysis 
To determine whether 
90-day refills at 
community pharmacies 
could improve 
adherence, minimise 
wastage and control 
costs. 
Medicaid patients Not explicitly 
reported; 
pharmacy 
claims data 
(Walgreens) 
• Anti-depressants 
(SSRIs) 
• Diabetic medications 
(oral hypoglycemics) 
• Anti-hypertensives 
• Lipid lowering agents 
(statins) 
90 day prescription (day 
supply greater than or 
equal to 84 days) 
compared to 30 day 
prescription (day supply 
less than 84 days) 
52,898 • Adherence 
• Cost 
• Wastage 
• Other 
(persistency) 
 
 
1 year 
Walton 2001[34] 
USA 
 
Cross-sectional 
study and cost 
To investigate the 
relative roles that fill 
quantity, dispensing 
costs, and wasted 
medication play in the 
total cost of outpatient 
Outpatients 
receiving  ongoing 
care and new to 
treatment through 
Veteran 
Administration's 
Outpatient 
prescription 
data from the 
Veteran 
Administration's 
Chicago Health 
• Lipid lowering agents 
(statins) 
90-day supply 
compared to 30-day 
supply 
16,990 
prescriptions 
• Cost 
• Wastage 
 
1 year 
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Reference, 
country, and 
study design 
Aim Participants Setting Medication 
evaluated 
Comparison Total sample 
size  
(patients 
unless 
otherwise 
stated) 
Outcomes 
measured 
Study 
length 
analysis 
 
prescriptions Chicago Health 
Care System 
Care System 
 
 Page 12 
Appendix 4: Studies that evaluated medication adherence 
Reference,  
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Adherence measurement (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply 
(unless otherwise 
stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size  
Dichotomous outcomes (≥80% adherence) 
Batal 2007[23] 
 
Retrospective 
cohort 
• Lipid lowering 
agents (statins) 
Pharmacy refills; each patient’s 
adherence score was calculated as 
their days of drug acquired divided 
by their days in the study (days 
from first prescription fill to last 
prescription fill). Primary outcome 
was proportion with ≥ 80% 
adherence. 
3 years 60-day supply: 
1307/2553 (51%) 
 
303/833 (36%) 
 
OR 0.53 (95% CI: 0.45, 0.62)1 
Domino 
2011[35] 
 
Before and after 
controlled study 
with a cost 
consequence 
analysis 
 
• Anti-depressants  
• Anti-psychotics 
• Anti- 
hypertensives  
• Diabetic 
medications  
• Seizure disorder 
medications 
• Lipid lowering 
agents (statins)  
Proportion of days covered (PDC) 
measure; calculates daily indicators 
of medication used divided by the 
number of days in the quarter. The 
outcome was reported as 
difference-in-difference-in-
differences2 in the percent of 
quarters in which individuals had 
PDC ≥ 80% 
18 months NR NR Statins:  -0.132 (0.025), p<0.01 
Diabetes: -0.053 (0.017), p<0.01 
Antihypertensives: -0.083 (0.006), 
p<0.01 
Seizure disorder:  -0.022 (0.014), 
p=ns 
Antidepressants:  -0.027 (0.021), 
p=ns 
Antipsychotics 0.004 (0.018), p=ns 
 
Hermes 
2010[25] 
*Abstract 
 
Retrospective 
cohort 
• Anti-hypertensives 
• Diabetic 
medications 
• Cholesterol 
lowering agents 
Proportion of days covered (PDC) 
(no further details reported). 
Primary outcome was the 
proportion with a PDC ≥ 80%. 
540 days Cholesterol lowering: 
5,4143/ 7,219 (74.9%) 
 
Anti- hypertensives: 
7,928/ 9,405 (84.3%)  
 
Diabetic medications: 
1,221/ 1,578 (77.4%) 
Cholesterol-lowering: 20,820/ 
31,982 (65.1%) 
 
Anti - hypertensives: 41,064/ 
53,192 (77.2%)  
 
Diabetic medications: 6,094/ 
8,844 (68.9%) 
Cholesterol-lowering:4 OR 0.62 
(95% CI: 0.59, 0.66) 
 
Anti-hypertensives: OR 0.63 (95% 
CI: 0.59, 0.67) 
 
Diabetic medications: OR 0.65 
(95% CI: 0.57, 0.74) 
Pfeiffer 
2012[28] 
• Anti-depressants Proportion of patients who received 
at least 180 days of an 
7 years 67,0775/ 87,000 
(77.1%) 
‘Less than a 90 day supply’: OR 0.21 (95% CI: 0.21, 0.22) 
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Reference,  
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Adherence measurement (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply 
(unless otherwise 
stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size  
 
Retrospective 
cohort 
antidepressant treatment out of the 
231-day period following the index 
prescription. The primary outcome 
was the proportion with >80% 
adherence.  
123,993/ 296,634 (41.8%) 
 
 
Schmittdiel 
2015[33] 
 
Cross-sectional 
study 
• Anti-hypertensives 
(ACE inhibitors; 
angiotensin II 
receptor blockers) 
• Diabetic 
medications (oral 
anti-
hyperglycemics) 
• Lipid lowering 
agents (statins) 
Proportion of Days Covered (PDC); 
the percent of days in the 
measurement period "covered" by 
prescription fills for the same 
medication or medications in the 
same therapeutic category. Primary 
outcome was predictors of 
adherence modelled as a 
dichotomous outcome in a Poisson 
regression model. 
Up to 1 
year 
NR NR Estimated RR of being adherent 
(PDC ≥0.8) (reference group with 
<31 days’ supply):6 
ACEI/ARB: 61-90 days 1.35; >90 
days 1.61  
Oral diabetes medications: 61-90 
days 1.48; >90 days 1.61  
Statins: 61-90 days 1.47; >90 days 
1.61 (p<0.001 for all) 
Continuous (mean PDC or MPR) 
Domino 
2011[35] 
*Same as 
above 
Before and after 
controlled study 
with a cost 
consequence 
analysis 
 
• Anti-depressants  
• Anti-psychotics 
• Anti- 
hypertensives 
• Diabetic 
medications  
• Seizure disorder 
medications 
• Lipid lowering 
agents (statins)  
Proportion of days covered (PDC) 
measure; as above. 
 
18 months  NR  
 
NR 
 
Statins: -0.080 (0.012), p<0.01 
Diabetes: -0.034 (0.008), p<0.01 
Antihypertensives: -0.045 (0.002), 
p<0.01 
Seizure disorder:  -0.009 (0.006), 
p=ns 
Antidepressants:  -0.030 (0.010), 
p<0.01 
Antipsychotics:  -0.010 (0.008), 
p=ns 
Jiang 2007[26] 
*Abstract 
 
Retrospective 
cohort 
• Anti-depressants 
(SSRIs) 
• Anti-hypertensives 
(ACE inhibitors) 
• Lipid lowering 
agents (statins) 
Medication Possession Ratio 
(MPR) (no further details reported) 
1 year Mandatory 90-days: 
0.7543 (SD not 
reported)7 (n=148) 
 
Voluntary 90-days: 
0.6895 (SD not 
reported) (n=582) 
0.3999 (SD not reported) 
(n=955) 
MD -0.30 (95% CI:-0.58, -0.03)8 
 
 
 
Schectman 42 medications: Number of days of therapy 9 months NR NR Based on multivariate analysis, 
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Reference,  
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Adherence measurement (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply 
(unless otherwise 
stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size  
2002[32] 
 
Cross-sectional 
study 
• Anti-hypertensives 
• Diabetic 
medications 
• Lipid lowering 
agents  
dispensed between first and last 
refill, divided by interval between 
first and last refill. Primary outcome 
was predictors of adherence 
modelled in a multivariable linear 
regression model. No details on 
whether or not MPR was capped at 
100%. 
each 30-day increment in 
prescription drug supply (maximum 
supply was 90 days) was 
associated with a 5.7% increase in 
mean adherence (p<0.0001)9 
Steiner 
1993[30] 
 
Retrospective 
cohort 
• Digoxin The proportion of prescribed dose 
of maintenance medication 
obtained. Calculated as the total 
days' supply divided by the number 
of days between the first and last 
fills.  
14 months 31 to 89 days: 
103.6%* (SD 26.6) 
(n=41) 
 
≥ 90 days: 
113.0%* (SD 21.4) 
(n=46) *presented as 
rate in the forest plot 
89.7% (SD 34.9) (n=27) ≥ 90 days vs. ≤30 days: MD -0.23 
(95% CI: -0.38, -0.09) 
 
 
 
Taitel 2012[31] 
 
Retrospective 
cohort with a 
cost 
consequence 
analysis 
• Anti-depressants 
(SSRIs) 
• Diabetic 
medications (oral 
hypoglycemics) 
• Anti-hypertensives 
• Lipid lowering 
agents (statins) 
Medication possession ratio (MPR); 
sum of the days’ supply for each 
therapeutic area divided by 365, the 
number of days in the follow-up 
period. 
1 year Anti-hypertensives: 
0.910 (SD 0.174)10 
(n=5,835) 
 
Statins: 0.819 (SD 
0.194) (n=2,162) 
 
SSRIs: 0.817 (SD 
0.196) (n=266) 
 
Hypoglycemics: 0.875 
(SD 0.190) (n=1,511) 
Anti-hypertensives: 0.774 (SD 
0.292) (n= 33,009) 
 
Statins: 0.671 (SD 0.278) 
(n=12,136) 
 
SSRIs: 0.611 (SD 0.295) 
(n=7,017) 
 
Hypoglycemics: 0.775 (SD 
0.289) (n=11,842) 
Anti-hypertensives: MD -0.14 (95% 
CI: -0.14, -0.13) 
 
Statins: MD -0.15 (95% CI: -0.16, -
0.14) 
 
SSRIs: MD -0.21 (95% CI: -0.23, -
0.18) 
 
Hypoglycemics: MD -0.12 (95% CI: 
-0.13, -0.11) 
Notes: MD = mean difference, NR = not reported, OR = Odd Ration, RR = Risk Ratio,  
1The authors reported an adjusted RR 1.41 (95% CI: 1.28 to 1.55), p<0.01, controlling for age, gender, race, co-payment, comorbidities, and insurance status; Given that this is 
a retrospective cohort study, we have presented the effect size as an odds ratio;  
2 Differences-in-differences-in-differences measures = differences from baseline to follow-up between two states (North Carolina and Georgia);  
3
 Numerators were calculated from data presented in the abstract;  
4
 The authors reported the following effect sizes: Cholesterol OR 0.60 (95% CI: 0.57 to 0.64), p<0.001; Hypertension OR 0.60 (0.56 to 0.63), p<0.001; Diabetes OR 0.61 
(95%CI 0.53 to 0.70), p<0.001. Our calculated ORs, as presented in the forest plot and table, are similar;  
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5
 Numerators were calculated from data presented in the text; 
6 Regression models adjusted for site and whether patient was enrolled in health plan;  
7 The authors were contacted, but SDs were not available; 
8 We combined the means from the mandatory and voluntary 90 days groups. Standard deviations were imputed in order to calculate an effect size (based on p<0.01);  
9 In the multivariate model for mean adherence, each day supply had a parameter estimate of 0.19, so that for 30 days, adherence was estimated to be 5.7%;  
10 Means and SDs were obtained from the study authors.  
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Appendix 5: Studies that evaluated medication wastage 
Reference, 
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Wastage definition and calculation (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply (unless 
otherwise stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size 
Percentage of days’ supply wasted  
Faris 2010[24] 
*Abstract 
 
Retrospective 
cohort 
Medications for: 
• Multiple sclerosis 
• Rheumatoid 
arthritis 
• Oncology 
• Growth hormone 
Wastage occurred when patients 
switched medication or stopped taking 
therapy (drop off waste). Outcome 
measured: proportion of days’ supply 
wasted calculated as the sum of switch 
waste and drop off waste, divided by total 
days supplied. 
 
21 months Multiple sclerosis: 2.44% 
Rheumatoid arthritis: 2.73% 
Oncology: 1.90% 
Growth hormone: 4.28% 
(sample sizes and SDs were not 
reported) 
Multiple sclerosis: 2.55%  
Rheumatoid arthritis: 3.97%  
Oncology: 3.42%  
Growth hormone: 3.54% 
(sample sizes and SDs were not 
reported) 
An effect size was not 
reported and could 
not be calculated 
Ryvkin 
2009[29] 
*Abstract 
 
Retrospective 
cohort 
 
• Anti-
hypertensives 
• Lipid-lowering 
agents  
• Anti-ulcers 
(Proton pump 
inhibitors) 
Defined as a switch within therapeutic 
area. Outcome measured: proportion of 
days’ supply wasted.  
 
Not 
reported 
Anti-hypertensives: 
2.0% (sample sizes and SDs not 
reported) 
 
Lipid-lowering agents: 
1.2% (sample sizes and SDs not 
reported) 
 
Proton pump inhibitors: 
0.7% (sample sizes and SDs not 
reported) 
Anti-hypertensives: 
2.1% (sample sizes and SDs 
not reported) 
 
Lipid-lowering agents: 
0.4% (sample sizes and SDs 
not reported) 
 
Proton pump inhibitors: 
0.7% days (sample sizes and 
SDs not reported) 
An effect size was not 
reported and could 
not be calculated 
Mean number of days’ supply wasted  
Jiang 
2007[26] 
*Abstract 
 
Retrospective 
cohort 
• Anti-depressants 
(SSRIs) 
• Anti-
hypertensives 
(ACE inhibitors) 
• Lipid lowering 
agents (statins) 
Wastage occurred either when patients 
switched to different medication within the 
same therapeutic area or to similar 
medication having different strength and 
that the patients' actual days' supply was 
less than the dispensed days' supply. 
Outcome measured: total days' supply 
wasted among a normalised 30-day 
period.  
1 year All therapeutic areas: 
Mandatory 90 days:  2.5 days per 
30-day period (n=148) 
 
Voluntary 90 days: 2.2 days per 
30-day period (n=582) 
 
All therapeutic areas: 
2.3 days per 30-day period 
(n=955) 
MD -0.10 (95% CI: -
0.20, -0.00)1 
 
 
Murphy 
2012[27] 
• Anti-depressants 
(SSRIs; 
Wastage was defined as an excess days’ 
supply of medication resulting from a 
1 year Anti-depressants:  
SSRIs: 0.142 days per 30-day 
Anti-depressants: 
SSRIs: 0.157 days per 30-day 
Anti-depressants:  
SSRIS: MD 0.02 (95% 
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Reference, 
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Wastage definition and calculation (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply (unless 
otherwise stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size 
 
Retrospective 
cohort 
Tricyclics) 
• Diabetic 
medications 
(biguanides; 
insulin)  
• Anti-
hypertensives 
(Alpha-beta 
blockers; ACE 
inhibitors; 
Angiotensin II 
receptor 
antagonists; 
calcium channel 
blockers; 
cardioselective 
beta-blockers; 
Loop diuretics; 
Thiazides) 
• Lipid lowering 
agents (HMG 
CoA reductase 
inhibitors; Fibric 
acid derivatives) 
• Thyroid 
hormones 
switch in medication within the same 
therapeutic areaor to the same 
medication but different strength 
occurring before the expected refill date.  
Outcome measured: mean number of 
days wasted calculated as the sum of the 
excess days divided by the total number 
of fills which were converted to 30-day 
equivalents.  
 
 
period (SDs not reported) 
(n=3,337) 
Tricyclics: 0.147 days per 30-day 
period (n=456) 
 
Diabetic medications:  
Insulins: 0.512 days per 30-day 
period (n=546) 
Biguanides: 0.131 days per 30-
day period (n=1938) 
 
Anti-hypertensives:  
Cardioselective beta-blockers: 
0.144 days per 30-day period 
(n=4,353) 
Alpha beta-blockers: 0.202 days 
per 30-day period (n=554) 
Calcium channel blockers: 0.156 
days per 30-day period (n=3,246) 
ACE inhibitors: 0.134 days per 
30-day period (n=4,786) 
Angiotensin II receptor 
antagonists: 0.247 days per 30-
day period (n=2,224) 
Loop diuretics: 0.100 days per 30-
day period (n=556) 
Thiazides: 0.062 days per 30-day 
period (n=1,778) 
 
Lipid lowering agents: 
HMG CoA reductase inhibitors: 
0.118 days per 30-day period 
(n=10,674) 
Fibric acid derivatives: 0.079 days 
period (SDs not reported) 
(n=7,969) 
Tricyclics: 0.131 days per 30-
day period (n=1,091) 
 
Diabetic medications: 
Insulins: 0.281 days per 30-day 
period (n=1,545) 
Biguanides: 0.082 days per 30-
day period (n=3,429) 
 
Anti-hypertensives:  
Cardioselective beta-blockers: 
0.087 days per 30-day period 
(n=5,458) 
Alpha beta-blockers: 0.114 days 
per 30-day period (n=934) 
Calcium channel blockers: 
0.127 days per 30-day period 
(n=4,249) 
ACE inhibitors: 0.102 days per 
30-day period (n=6,371) 
Angiotensin II receptor 
antagonists: 0.117 days per 30-
day period (n=2,451) 
Loop diuretics: 0.151 days per 
30-day period (n=1,179) 
Thiazides: 0.024 days per 30-
day period (n=2,335) 
 
Lipid lowering agents: 
HMG CoA reductase inhibitors: 
0.086 days per 30-day period 
(n=10,410) 
CI: -0.03, 0.06)2 
Tricyclics:  MD -0.02 
(95% CI: -0.06, 0.03) 
Diabetic medications: 
Insulins: MD -0.23 
(95% CI: -0.43, -0.04) 
Biguanides:  
MD -0.02 (95% CI: -
0.06, 0.03) 
 
Anti-hypertensives:  
Cardioselective beta-
blockers: MD -0.06 
(95% CI: -0.11, -0.01) 
Alpha beta-blockers: 
MD -0.09 (95% CI: -
0.20, 0.03) 
Calcium channel 
blockers: MD -0.03 
(95% CI: -0.08, 0.02) 
ACE inhibitors: MD -
0.03 (95% CI: -0.07, 
0.00) 
Angiotensin II 
receptor antagonists: 
MD -0.13 (95% CI: -
0.24, -0.02) 
Loop diuretics: MD 
0.05 (95% CI: -0.06, 
0.16) 
Thiazides: MD -0.04 
(95% CI: -0.07, -0.00) 
 
Lipid lowering agents: 
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Reference, 
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Wastage definition and calculation (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply (unless 
otherwise stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size 
per 30-day period (n=1,236)  
 
Thyroid hormones: 0.383 days 
per 30-day period (n=4,846) 
 
Fibric acid derivatives: 0.079 
days per 30-day period 
(n=1,710)  
 
Thyroid hormones:  0.252 days 
per 30-day period (n=6,725) 
HMG CoA reductase 
inhibitors: MD -0.03 
(95% CI: -0.06, 0.00) 
Fibric acid derivatives: 
MD 0.0 (95% CI: 0.00, 
0.00) 
 
Thyroid hormones: 
MD -0.13 (95% CI: -
0.24, -0.02) 
Taitel 
2012[31] 
 
Retrospective 
cohort with a 
cost 
consequence 
analysis 
 
• Anti-depressants 
(SSRIs) 
• Diabetic 
medications (oral 
hypoglycemics) 
• Anti-
hypertensives  
• Lipid lowering 
agents (statins) 
Defined as a switch of drug type or 
strength within the same therapeutic area 
that occurred before the expected refill 
date. Outcome measured: average 
number of waste days.  
1 year Antihypertensives: 
9.211 days (SD 30.284)3 
(n=5,835) 
 
Statins: 
5.757 days (SD 22.205) (n=2,162) 
 
SSRIs: 
10.425 days (SD 32.463) (n=266) 
 
Hypoglycemics: 
7.899 days (SD 25.385) (n=1,511) 
Antihypertensives: 
4.037 days (SD 16.236) (n= 
33,009) 
 
Statins: 
2.251 days (SD 10.673) 
(n=12,136) 
 
SSRIs: 
3.501 days (SD 12.941) 
(n=7,017) 
 
Hypoglycemics: 
3.289 days (SD 13.441) 
(n=11,842) 
Antihypertensives: 
MD -5.17 (95% CI: -
5.97, -4.38) 
 
Statins: 
MD -3.51 (95% CI: -
4.46, -2.55) 
 
SSRIs: 
MD -6.92 (95% CI: -
10.84, -3.01) 
 
Hypoglycemics: 
MD -4.61 (95% CI: -
5.91, -3.31) 
Walton 
2001[34] 
 
Cross-
sectional 
study 
• Lipid lowering 
agents (HMG 
CoA reductase 
inhibitors) 
Defined as a switch within therapeutic 
area. Outcome measured: mean number 
of days wasted calculated as the 
difference between the average quantity 
dispensed and the average quantity used 
for each group. If a switch occurred, the 
quantity used was calculated as the 
difference between the date the first 
prescription was dispensed and the date 
the second, different prescription was 
1 year 5.33 days (SD not reported) 
(n=3,635) 
1.06 days (SD not reported) ‘for 
each 30-day fill period’ 
(n=13.355)  
 
 
An effect size was not 
reported and could 
not be calculated. 
 It is not clear if these 
results are 
standardised for the 
same time period and 
therefore if the results 
are comparable. 
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Reference, 
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Wastage definition and calculation (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply (unless 
otherwise stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size 
dispensed.  
Proportion of patients that wasted medication  
Ryvkin 
2009[29] 
*Abstract 
 
Retrospective 
cohort 
 
• Anti-
hypertensives 
• Lipid-lowering 
agents  
• Anti-ulcers 
(Proton pump 
inhibitors)1 
Defined as a switch within therapeutic 
area. Outcome measured proportion of 
patients that wasted medication.  
Not 
reported 
Anti-hypertensives: 
5.2% (sample sizes not reported) 
 
Lipid-lowering agents: 
2.9% (sample sizes not reported) 
 
Proton pump inhibitors: 
1.8% (sample sizes not reported) 
Anti-hypertensives: 
6.3% (sample sizes not 
reported) 
 
Lipid-lowering agents: 
1.2% (sample sizes not 
reported) 
 
Proton pump inhibitors: 
1.9% (sample sizes not 
reported) 
An effect size was not 
reported and could 
not be calculated 
Taitel 
2012[31] 
 
Retrospective 
cohort with a 
cost 
consequence 
analysis 
 
• Anti-depressants 
(SSRIs) 
• Diabetic 
medications (oral 
hypoglycemics) 
• Anti-
hypertensives  
• Lipid lowering 
agents (statins) 
Defined as a switch of drug type or 
strength within the same therapeutic area 
that occurred before the expected refill 
date. Outcome measured: percentage of 
patients that wasted medication.  
1 year Anti-hypertensives: 
7124/5,835 (12.2%) 
 
Statins: 
212/2,162 (9.8%) 
 
SSRIs: 
39/266 (14.7%) 
 
Hypoglycemics: 
175/1,511 (11.6%) 
Anti-hypertensives: 
3,928/33,009 (11.9%) 
 
Statins: 
1,104/12,136 (9.1%) 
 
SSRIs: 
975/7,017 (13.9%) 
 
Hypoglycemics: 
1,255/11,842 (10.6%) 
Anti-hypertensives: 
OR 0.97 (95% CI: 
0.89, 1.06) 
 
Statins: 
OR 0.84 (95% CI: 
0.72, 0.98) 
 
SSRIs: 
OR 0.94 (95% CI: 
0.66 1.33) 
 
Hypoglycemics: 
OR 0.90 (95% CI: 
0.76, 1.07) 
Walton 
2001[34] 
 
Cross-
• Lipid lowering 
agents (HMG 
CoA reductase 
inhibitors) 
Defined as a switch within therapeutic 
area. Outcome measured: proportion of 
patients that switched.  
1 year  545/3,635 (15.0%) 
 
1,909/13,355 (14.3%) OR 0.95 (95% CI: 
0.85, 1.05) 
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Reference, 
study type 
Condition(s)/ 
Medication(s) 
evaluated 
Wastage definition and calculation (as 
reported by the study authors) 
Duration 
of study 
90-days’ supply (unless 
otherwise stated) 
30-days’ supply (unless 
otherwise stated) 
Effect size 
sectional 
study 
Notes: MD = mean difference, OR = odds ratio, SD = standard deviation 
1 We combined the means from the mandatory and voluntary 90 day groups. Standard deviations were imputed in order to calculate an effect size (based on p>0.05); 
2 Standard deviations were imputed in order to calculate an effect size (p values were reported for each comparison). 
3
 Means and SDs were obtained from the study authors; 
4 Numerators have been calculated based on overall sample sizes and percentages. 
 
Appendix 6: Risk of bias assessment 
Reference 
Bias due to 
confounding 
Bias in selection 
of participants 
into the study 
Bias in 
classification of 
interventions 
Bias due to 
departures from 
intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement 
of outcomes 
Bias in selection 
of the reported 
result 
Overall bias 
Batal 2007 Low Moderate Low Low Low Low Low Moderate 
Domino 2011 Low Low Low Moderate Moderate Low Low Moderate 
Faris 2010* No information No information Low No information No information Low No information No information 
Hermes 2010* Moderate Moderate Low No information No information Low No information No information 
Jiang 2007* No information Moderate Low No information No information Low No information No information 
Murphy 2012 Low Moderate Low Low Moderate Low Low Moderate 
Pfeiffer 2012 Low Moderate Low Low Low Low Low Moderate 
Ryvkin 2009* No information No information Low No information No information Low No information No information 
Schectman 2002 Moderate No information No information Moderate No information Low Low Moderate 
Schmittdiel 2015 Low Moderate Low Moderate Low Low Low Moderate 
Steiner 1993 Serious Moderate Low Low No information Low Low Serious 
Taitel 2012 Moderate/Serious Moderate Serious Moderate Low Low Low Serious 
Walton 2001 Moderate/Serious Moderate/Serious Low  Low Low Low Low Moderate 
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